The objective of this task order supports niaids pandemic response repository through microbial and immunologic surveillance and epidemiology (premise)
Active Awarded Last action
- Contract number
- 75N91023F00016
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,442,372
Award facts
- Contract value 100% obligated
- $6,442,372.00 Current and potential, with all options
- Completion date 45% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $3,300,590 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $603,531 | |
| Original award | $2,538,251 |
About this award
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The objective of this task order is to support NIAID's Pandemic Response Repository through microbial and immunologic surveillance and epidemiology, known as the PREMISE program. The contract has a ceiling value of $6,442,372.00 and a period of performance through July 14, 2030. The contract does not have a set-aside designation, indicating it was competed on a full and open basis. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for the National Cancer Institute, providing comprehensive biomedical research and facilities support services to federal agencies, with a focus on NIH.
Quick answers
Who was awarded contract 75N91023F00016?
75N91023F00016 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2023.
How much is contract 75N91023F00016 worth?
The government has obligated $6,442,372 on 75N91023F00016.
Which agency awarded contract 75N91023F00016?
National Cancer Institute (National Institutes of Health) awarded 75N91023F00016, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91023F00016 an order under another contract?
Yes. 75N91023F00016 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91023F00016 competed?
The extent of competition for 75N91023F00016 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award